Aspen Prices Autologous Cell Therapy IPO

Company Aspen Neuroscience (ASPE) Event Type Initial public offering priced Modality Autologous iPSC-derived dopaminergic neuron precursor cell therapy Asset Sasineprocel (ANPD001) Target Dopaminergic neuron replacement (putamen) Disease Area Parkinson’s disease Summary Aspen Neuroscience priced a US IPO on 29 October: 9,375,000 primary shares at $15,…